当前位置: 首页 >> 检索结果
581. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study.
作者: Ikue Watari.;Shiro Oka.;Shinji Tanaka.;Taiki Aoyama.;Hiroki Imagawa.;Takayoshi Shishido.;Shigeto Yoshida.;Kazuaki Chayama.
来源: BMC Gastroenterol. 2013年13卷108页
Treatment of low-dose aspirin (LDA)-induced small-bowel injury has not been established. Polaprezinc, a chelate of zinc and L-carnosine, may be efficacious for such injury. We conducted a pilot randomized controlled study to investigate whether polaprezinc is effective against LDA-induced small-bowel injuries.
582. Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study.
作者: Dorota Koziarska.;Ewa Wunsch.;Małgorzata Milkiewicz.;Maciej Wójcicki.;Przemysław Nowacki.;Piotr Milkiewicz.
来源: BMC Gastroenterol. 2013年13卷107页
Mini-Mental State Examination (MMSE) is one of the most commonly used methods in the assessment of cognitive mental status. MMSE has been used in hepatology but its usefulness in the evaluation of hepatic encephalopathy (HE) has never been properly assessed. The aim of the study was to investigate the value of MMSE in detection of HE in patients with cirrhosis.
583. Nitroglycerin 0.4% ointment vs placebo in the treatment of pain resulting from chronic anal fissure: a randomized, double-blind, placebo-controlled study.
作者: Scott M Berry.;Charles F Barish.;Raj Bhandari.;Gemma Clark.;Gregory V Collins.;Julian Howell.;John E Pappas.;Dennis S Riff.;Michael Safdi.;Ann Yellowlees.
来源: BMC Gastroenterol. 2013年13卷106页
Complications of chronic anal fissure (CAF) treatments are prompting interest in lower-risk therapies. This study was conducted to compare nitroglycerin (NTG) 0.4% ointment with placebo for pain associated with CAF.
584. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
作者: Patrick Marcellin.;Curtis Cooper.;Luis Balart.;Dominique Larrey.;Terry Box.;Eric Yoshida.;Eric Lawitz.;Peter Buggisch.;Peter Ferenci.;Martin Weltman.;Emily Labriola-Tompkins.;Sophie Le Pogam.;Isabel Nájera.;Denise Thomas.;Gregory Hooper.;Nancy S Shulman.;Ying Zhang.;Mercidita T Navarro.;Chin Yin Lim.;Michael Brunda.;Norah A Terrault.;Ellen S Yetzer.
来源: Gastroenterology. 2013年145卷4期790-800.e3页
The combination of a hepatitis C virus (HCV) protease inhibitor, peginterferon, and ribavirin is the standard of care for patients with HCV genotype 1 infection. We report the efficacy and safety of response-guided therapy with danoprevir (a potent second-generation protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these patients.
585. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.
作者: Julián Panés.;Antonio López-Sanromán.;Fernando Bermejo.;Valle García-Sánchez.;Maria Esteve.;Yolanda Torres.;Eugeni Domènech.;Marta Piqueras.;María Gomez-García.;Ana Gutiérrez.;Carlos Taxonera.;Miquel Sans.; .
来源: Gastroenterology. 2013年145卷4期766-74.e1页
A small placebo-controlled trial reported the efficacy of mercaptopurine therapy for children newly diagnosed with Crohn's disease, yet little is known about the efficacy of early thiopurine therapy in adults.
586. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
作者: William J Sandborn.;Brian G Feagan.;Colleen Marano.;Hongyan Zhang.;Richard Strauss.;Jewel Johanns.;Omoniyi J Adedokun.;Cynthia Guzzo.;Jean-Frederic Colombel.;Walter Reinisch.;Peter R Gibson.;Judith Collins.;Gunnar Järnerot.;Paul Rutgeerts.; .
来源: Gastroenterology. 2014年146卷1期96-109.e1页
Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-α (TNFα), was evaluated as maintenance therapy in TNFα antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy.
587. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
作者: William J Sandborn.;Brian G Feagan.;Colleen Marano.;Hongyan Zhang.;Richard Strauss.;Jewel Johanns.;Omoniyi J Adedokun.;Cynthia Guzzo.;Jean-Frederic Colombel.;Walter Reinisch.;Peter R Gibson.;Judith Collins.;Gunnar Järnerot.;Toshifumi Hibi.;Paul Rutgeerts.; .
来源: Gastroenterology. 2014年146卷1期85-95; quiz e14-5页
Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) -α, for treatment of ulcerative colitis (UC). We evaluated subcutaneous golimumab induction therapy in TNF-α antagonist-naïve patients with moderate-to-severe UC despite conventional treatment.
588. Equal efficacy of endoscopic and surgical cystogastrostomy for pancreatic pseudocyst drainage in a randomized trial.
作者: Shyam Varadarajulu.;Ji Young Bang.;Bryce S Sutton.;Jessica M Trevino.;John D Christein.;C Mel Wilcox.
来源: Gastroenterology. 2013年145卷3期583-90.e1页
Although surgery is the standard technique for drainage of pancreatic pseudocysts, use of endoscopic methods is increasing. We performed a single-center, open-label, randomized trial to compare endoscopic and surgical cystogastrostomy for pancreatic pseudocyst drainage.
589. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
作者: Sunder Mudaliar.;Robert R Henry.;Arun J Sanyal.;Linda Morrow.;Hanns-Ulrich Marschall.;Mark Kipnes.;Luciano Adorini.;Cathi I Sciacca.;Paul Clopton.;Erin Castelloe.;Paul Dillon.;Mark Pruzanski.;David Shapiro.
来源: Gastroenterology. 2013年145卷3期574-82.e1页
Obeticholic acid (OCA; INT-747, 6α-ethyl-chenodeoxycholic acid) is a semisynthetic derivative of the primary human bile acid chenodeoxycholic acid, the natural agonist of the farnesoid X receptor, which is a nuclear hormone receptor that regulates glucose and lipid metabolism. In animal models, OCA decreases insulin resistance and hepatic steatosis.
590. A multi-centre randomised double-blind placebo-controlled trial to evaluate the value of a single bolus intravenous alfentanil in CT colonography.
作者: Thierry N Boellaard.;Marije P van der Paardt.;Markus W Hollmann.;Susanne Eberl.;Jan Peringa.;Lex J Schouten.;Giedre Kavaliauskiene.;Jurgen H Runge.;Jeroen A W Tielbeek.;Jaap Stoker.
来源: BMC Gastroenterol. 2013年13卷94页
Pain is common during colonic insufflation required for CT colonography. We therefore evaluate whether a single intravenous alfentanil bolus has a clinically relevant analgesic effect compared with placebo in patients undergoing CT colonography.
591. Search for atoxic cereals: a single blind, cross-over study on the safety of a single dose of Triticum monococcum, in patients with celiac disease.
作者: Barbara Zanini.;Beatrice Petroboni.;Tarcisio Not.;Nicola Di Toro.;Vincenzo Villanacci.;Francesco Lanzarotto.;Norberto Pogna.;Chiara Ricci.;Alberto Lanzini.
来源: BMC Gastroenterol. 2013年13卷92页
Cereals of baking quality with absent or reduced toxicity are actively sought as alternative therapy to a gluten-free diet (GFD) for patients with coeliac disease (CD). Triticum monococcum, an ancient wheat, is a potential candidate having no toxicity in in-vitro and ex-vivo studies. The aim of our study was to investigate on the safety of administration of a single dose of gluten of Tm in patients with CD on GFD.
592. In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity.
作者: Ricard Farré.;Hanne Vanheel.;Tim Vanuytsel.;Tatsuhiro Masaoka.;Hans Törnblom.;Magnus Simrén.;Lukas Van Oudenhove.;Jan F Tack.
来源: Gastroenterology. 2013年145卷3期566-73页
Hypersensitivity to gastric distention, an important feature of functional dyspepsia, is assessed by stepwise balloon distention of the proximal stomach in fasting patients. However, symptoms of functional dyspepsia are often worse after a meal, so studies of postprandial balloon distentions might be more relevant. We compared the effects of fasting and postprandial stomach distention in patients with functional dyspepsia.
593. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study.
作者: Takanori Kuramoto.;Eiji Umegaki.;Sadaharu Nouda.;Ken Narabayashi.;Yuichi Kojima.;Yukiko Yoda.;Kumi Ishida.;Ken Kawakami.;Yosuke Abe.;Toshihisa Takeuchi.;Takuya Inoue.;Mitsuyuki Murano.;Satoshi Tokioka.;Kazuhide Higuchi.
来源: BMC Gastroenterol. 2013年13卷85页
Proton-pump inhibitors such as omeprazole are a standard treatment to prevent non-steroidal anti-inflammatory drug-induced upper gastrointestinal mucosal injuries. However, it is unclear which drugs may protect against all NSAID-induced digestive-tract injuries. Here, we compare the efficacy of the gastromucoprotective drug irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal injury in healthy subjects.
594. Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study.
作者: Makoto Sasaki.;Naotaka Ogasawara.;Yasushi Funaki.;Mari Mizuno.;Akihito Iida.;Chiho Goto.;Satoshi Koikeda.;Kunio Kasugai.;Takashi Joh.
来源: BMC Gastroenterol. 2013年13卷81页
Recently, the relationship between gut microbiota and obesity has been highlighted. The present randomized, double-blind, placebo-controlled study aimed to evaluate the efficacy of transglucosidase (TGD) in modulating blood glucose levels and body weight gain in patients with type 2 diabetes mellitus (T2DM) and to clarify the underlying mechanism by analyzing the gut microbiota of T2DM patients.
595. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates.
作者: Jessica R Biesiekierski.;Simone L Peters.;Evan D Newnham.;Ourania Rosella.;Jane G Muir.;Peter R Gibson.
来源: Gastroenterology. 2013年145卷2期320-8.e1-3页
Patients with non-celiac gluten sensitivity (NCGS) do not have celiac disease but their symptoms improve when they are placed on gluten-free diets. We investigated the specific effects of gluten after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates (fermentable, oligo-, di-, monosaccharides, and polyols [FODMAPs]) in subjects believed to have NCGS.
596. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
作者: Jacques Cosnes.;Anne Bourrier.;David Laharie.;Stéphane Nahon.;Yoram Bouhnik.;Franck Carbonnel.;Matthieu Allez.;Jean-Louis Dupas.;Jean-Marie Reimund.;Guillaume Savoye.;Pauline Jouet.;Jacques Moreau.;Jean-Yves Mary.;Jean-Frédéric Colombel.; .
来源: Gastroenterology. 2013年145卷4期758-65.e2; quiz e14-5页
Immunomodulator therapy is effective for patients with Crohn's disease (CD) but has not been shown to affect disease progression, presumably because it is given too late after diagnosis. We compared the efficacy of early treatment (within 6 months after diagnosis) with azathioprine versus conventional management of patients at high risk for disabling disease.
597. T.E.A. Study: three-day ertapenem versus three-day Ampicillin-Sulbactam.
作者: Fausto Catena.;Carlo Vallicelli.;Luca Ansaloni.;Massimo Sartelli.;Salomone Di Saverio.;Riccardo Schiavina.;Eddi Pasqualini.;Annalisa Amaduzzi.;Federico Coccolini.;Michele Cucchi.;Daniel Lazzareschi.;Gian Luca Baiocchi.;Antonio D Pinna.
来源: BMC Gastroenterol. 2013年13卷76页
Intra-abdominal infections are one of the most common infections encountered by a general surgeon. However, despite this prevalence, standardized guidelines outlining the proper use of antibiotic therapy are poorly defined due to a lack of clinical trials investigating the ideal duration of antibiotic treatment. The aim of this study is to compare the efficacy and safety of a three-day treatment regimen of Ampicillin-Sulbactam to that of a three-day regimen of Ertapenem in patients with localized peritonitis ranging from mild to moderate severity.
598. Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website.
作者: Hazel Everitt.;Rona Moss-Morris.;Alice Sibelli.;Laura Tapp.;Nicholas Coleman.;Lucy Yardley.;Peter Smith.;Paul Little.
来源: BMC Gastroenterol. 2013年13卷68页
Many patients with IBS suffer on-going symptoms. The evidence base is poor for IBS drugs but they are widely prescribed and advised in Guidelines. Cognitive Behavioural Therapy (CBT) can be helpful, but availability is poor in the NHS. We developed a web-based CBT self-management programme (Regul8) in partnership with patients and trialled it and common IBS medications in an exploratory factorial RCT to test trial procedures and provide information for a larger trial.
599. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
作者: Leonard S Dove.;Anthony Lembo.;Charles W Randall.;Ronald Fogel.;David Andrae.;J Michael Davenport.;Gail McIntyre.;June S Almenoff.;Paul S Covington.
来源: Gastroenterology. 2013年145卷2期329-38.e1页
Simultaneous agonism of the μ-opioid receptor and antagonism of the δ-opioid receptor can reduce abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) without constipating side effects. We evaluated the efficacy and safety of a minimally absorbed, μ-opioid receptor agonist and δ-opioid receptor antagonist (eluxadoline) in a phase 2 study in patients with IBS-D.
600. Endoscopic suturing for transoral outlet reduction increases weight loss after Roux-en-Y gastric bypass surgery.
作者: Christopher C Thompson.;Bipan Chand.;Yang K Chen.;Daniel C DeMarco.;Larry Miller.;Michael Schweitzer.;Richard I Rothstein.;David B Lautz.;James Slattery.;Michele B Ryan.;Stacy Brethauer.;Phillip Schauer.;Mack C Mitchell.;Anthony Starpoli.;Gregory B Haber.;Marc F Catalano.;Steven Edmundowicz.;Annette M Fagnant.;Lee M Kaplan.;Mitchell S Roslin.
来源: Gastroenterology. 2013年145卷1期129-137.e3页
Weight regain or insufficient loss after Roux-en-Y gastric bypass (RYGB) is common. This is partially attributable to dilatation of the gastrojejunostomy (GJ), which diminishes the restrictive capacity of RYGB. Endoluminal interventions for GJ reduction are being explored as alternatives to revision surgery. We performed a randomized, blinded, sham-controlled trial to evaluate weight loss after sutured transoral outlet reduction (TORe).
|